nach oben

Current Hypertension Reports

Erschienen in:

01.02.2018 | Mechanisms of Hypertension (M Weir, Section Editor)

Pros and Cons of Intensive Systolic Blood Pressure Lowering

verfasst von: Holly Kramer, Richard Cooper

Erschienen in: Current Hypertension Reports | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The Systolic Blood Pressure Intervention Trial demonstrated significant decreases in cardiovascular events and total mortality with intensive systolic blood pressure lowering in adults with high cardiovascular risk in the absence of diabetes but benefits were accompanied by increased risk of adverse events.

Recent Findings

Over 100,000 deaths and 46,000 cases of heart failure may be prevented annually if intensive systolic blood pressure lowering is implemented in 17 million US adults who are age 50 years and older, and have high cardiovascular risk in the absence of diabetes and meet eligibility for the Systolic Blood Pressure Intervention Trial. However, the benefits of intensive SBP lowering will be accompanied by an excess of 43,000 cases of electrolyte abnormalities and 88,000 cases of acute kidney injury.

Summary

Physicians should consider implementation of intensive systolic blood pressure lowering in appropriate patients who understand the risks and benefits of this intervention.

Society of Actuaries. Build and blood pressure study. Chicago: Society of Actuaries; 1959.

Wiehl DG. Review: build and blood pressure. The Milbank Memorial Fund Quarterly. 1960;38(2):180–3. https://doi.org/10.2307/3348783.CrossRef

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.CrossRefPubMed

•• Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967 Dec 11; 202 (11):1028–1034. First randomized clinical trial of blood pressure lowering for prevention of cardiovascular events and mortality.

Freis ED. Changing attitudes to hypertension. Ann Intern Med. 1973;78(1):141–2. https://doi.org/10.7326/0003-4819-78-1-141.CrossRefPubMed

The Joint National Committee on Detection. Evaluation and treatment on high blood pressure. The 1980 report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. A cooperative study. JAMA. 1977;237:255–61.CrossRef

Cooper R, Sempos C, Hsieh SC, Kovar MG. Slowdown in the decline of stroke mortality in the United States, 1978–1986. Stroke. 1990;21(9):1274–9. https://doi.org/10.1161/01.STR.21.9.1274.CrossRefPubMed

•• Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT study group. Lancet. 1998;351(9118):1755–62. https://doi.org/10.1016/S0140-6736(98)04311-6. One of the largest clinical blood pressure lowering trials to date which examined the association between three different diastolic blood pressure targets and cardiovascular outcomes. CrossRefPubMed

•• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255–64. First clinical trial to examine whether lowering blood pressure in older adults with isolated elevated systolic blood pressure reduces stroke risk. CrossRef

10.

•• Veterans Administration Cooperative Study Group on Anti-hypertensive Agents. Effects of treatment on morbidity in hypertension: II-results in patients with diastolic blood pressure averaging 90 through114 mmHg. JAMA. 1970;213:1143–52. Second phase of the first clinical trial of blood pressure lowering for prevention of cardiovascular outcomes. CrossRef

11.

• Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet. 1991;338(8778):1281–5. https://doi.org/10.1016/0140-6736(91)92589-T. This trial examined the value of lowering blood pressure in adults age 70-84 years with a average SBP between 180-230 mmHg and a DBP of 90 mmHg or higher. CrossRefPubMed

12.

•• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–13. One of the first clinical trials examining the cardiovascular benefits of intensive blood pressure lowering in adults with diabetes. CrossRefPubMedCentral

13.

• Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757–64. https://doi.org/10.1016/S0140-6736(97)05381-6. An additional clinical trial of blood pressure reduction with a calcium channel blocker vs. placebo in adults age > 60 years ith isolated elevations in systolic blood pressure. CrossRefPubMed

14.

•• Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363(10):918–29. https://doi.org/10.1056/NEJMoa0910975. Landmark clinical trial examining intensive vs. standard blood pressure lowering in African Americans with chronic kidney disease clinically attributed to hypertension. CrossRefPubMedPubMedCentral

15.

• Estacio RO, Coll JR, Tran ZV, Schrier RW. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens. 2006;19(12):1241–8. https://doi.org/10.1016/j.amjhyper.2006.05.011. One of the first clinical trials examining benefits of lowering SBP below 140 mmhg in adults with type 2 diabetes. CrossRefPubMed

16.

• Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2):B54–64. This clinical trial examined the risk of microvascular complications with a diastolic blood pressure goal of 75 mmHg vs. a diastolic blood pressure goal of 80-89 mmHg in adults with type 2 diabetes and a diastolic blood pressure => 90 mmHg. PubMed

17.

• Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol. 2002;13(7):1733–9. https://doi.org/10.1097/01.ASN.0000018407.60002.B9. This trial examined benefits of standard vs. intensive blood pressure lowering in adults with polycystic kidney disease.

18.

• Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61(3):1086–97. https://doi.org/10.1046/j.1523-1755.2002.00213.x. One of the early trials examining the benefits of intensive systolic blood pressure lowering in adults with type 2 diabetes. CrossRefPubMed

19.

•• SPS3 Study Group, Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382(9891):507–15. Clinical trial examined the efficacy of a systolic blood pressure target < 130 mmHg vs. 130–149 mmHg for secondary stroke prevention. CrossRef

20.

•• Mancia G. Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010;122(8):847–9. https://doi.org/10.1161/CIRCULATIONAHA.110.960120. Landmark trial which examined intensive systolic blood pressure lowering vs. standard control in adults with type 2 diabetes. CrossRefPubMed

21.

•• Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group. N Engl J Med. 1994;330(13):877–84. https://doi.org/10.1056/NEJM199403313301301. This clinical trial compared a mean arterial blood pressure of 92 mmHg vs. 107 mmHg in 1, 585 adults with glomerular filtration rates between 25 to 55 ml/min/1.73 m2 body surface area.

22.

Lewis JB. Blood pressure control in chronic kidney disease: is less really more? J Am Soc Nephrol. 2010;21(7):1086–92. https://doi.org/10.1681/ASN.2010030236.CrossRefPubMed

23.

Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005;142(5):342–51. https://doi.org/10.7326/0003-4819-142-5-200503010-00009.

24.

Davis EM, Appel LJ, Wang X, Greene T, Astor BC, Rahman M, et al. Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial. Hypertension. 2011;57(6):1061–8. https://doi.org/10.1161/HYPERTENSIONAHA.111.169367.

25.

•• The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16. https://doi.org/10.1056/NEJMoa1511939. This landmark clinical trial demonstrated significant reductions in mortality with intensive systolic blood pressure lowering (< 120 mmHg) vs. standard systolic blood pressure lowering (< 140 mmHg) in adults with high cardiovascular risk. CrossRefPubMedCentral

26.

Beckett L, Godwin M. The BpTRU automatic blood pressure monitor compared to 24 hour ambulatory blood pressure monitoring in the assessment of blood pressure in patients with hypertension. BMC Cardiovasc Disord. 2005;5(1):18. https://doi.org/10.1186/1471-2261-5-18.CrossRefPubMedPubMedCentral

27.

Myers MGA. Short history of automated office blood pressure—15 years to SPRINT. J Clin Hypertens (Greenwich). 2016;18(8):721–4. https://doi.org/10.1111/jch.12820.CrossRef

28.

• Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387(10017):435–43. https://doi.org/10.1016/S0140-6736(15)00805-3. Meta-analysis of trials that examined the cardiovascular and mortality benefits of blood pressure targets below 140 mmHg.

29.

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am coll Cardiol. 2017;S0735-1097(17):41591-1.

30.

Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, et al. Hypertension Canada’s 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2016;32(5):569–88. https://doi.org/10.1016/j.cjca.2016.02.066.

31.

Ortiz E, James PA. Let’s not SPRINT to judgment about new blood pressure goals. Ann Intern Med. 2016;165(12):889–90. https://doi.org/10.7326/L16-0442.CrossRefPubMed

32.

• Bress AP, Kramer H, Khatib R, Beddhu S, Cheung AK, Hess R, et al. Potential deaths averted and serious adverse events incurred from adoption of the SPRINT (systolic blood pressure intervention trial) intensive blood pressure regimen in the United States: projections from NHANES (National Health and nutrition examination survey). Circulation. 2017;135(17):1617–28. https://doi.org/10.1161/CIRCULATIONAHA.116.025322. Observational study which estimates that over 100,000 deaths would be prevented annually if intensive systolic blood pressure lowering was implemented in U.S. adults with high cardiovascular risk.

33.

Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Generalizability of SPRINT results to the U.S. adult population. J Am Coll Cardiol. 2016;67(5):463–72. https://doi.org/10.1016/j.jacc.2015.10.037.CrossRefPubMed

34.

Mensah GA, Wei GS, Sorlie PD, Fine LJ, Rosenberg Y, Kaufmann PG, et al. Decline in cardiovascular mortality: possible causes and implications. Circ Res. 2017;120(2):366–80. https://doi.org/10.1161/CIRCRESAHA.116.309115.

35.

Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603. https://doi.org/10.1161/CIR.0000000000000485.

36.

• Moise N, Huang C, Rodgers A, Kohli-Lynch CN, Tzong KY, Coxson PG, et al. Comparative cost-effectiveness of conservative or intensive blood pressure treatment guidelines in adults aged 35–74 years: the cardiovascular disease policy model. Hypertension. 2016;68(1):88–96. https://doi.org/10.1161/HYPERTENSIONAHA.115.06814. Study estimates that intensive systolic blood pressure lowering is cost saving in men and cost effective in women.

37.

Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. III. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation. 1972;45(5):991–104. https://doi.org/10.1161/01.CIR.45.5.991.CrossRef

Titel: Pros and Cons of Intensive Systolic Blood Pressure Lowering
verfasst von: Holly Kramer
Richard Cooper
Publikationsdatum: 01.02.2018
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 2/2018
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-018-0806-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

New Developments in Hypertensive Encephalopathy

The Global Epidemic of the Metabolic Syndrome

Hypothalamic Ion Channels in Hypertension

Angiotensin-(1–7) and Alamandine on Experimental Models of Hypertension and Atherosclerosis

Vasopressin, Central Autonomic Control and Blood Pressure Regulation